3608 related articles for article (PubMed ID: 15882526)
1. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
3. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
[TBL] [Abstract][Full Text] [Related]
4. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
6. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
[TBL] [Abstract][Full Text] [Related]
7. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
Meriste S; Lutsar I; Tamm E; Willems P
Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
[TBL] [Abstract][Full Text] [Related]
9. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
[TBL] [Abstract][Full Text] [Related]
10. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
Dominicus R; Galtier F; Richard P; Baudin M
Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
Halperin SA; King J; Law B; Mills E; Willems P
Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
17. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
18. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
Bégué PC; Grimprel EM; Giovannangeli MD; Abitbol VI
Pediatr Infect Dis J; 1998 Sep; 17(9):804-9. PubMed ID: 9779766
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
20. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
